DRUG SEC-arkiveringar - Bright Minds Biosciences Inc.- Årsredovisning, Fullmaktsutlåtande, prospekt

Grundläggande statistik

CIK

1827401

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Bright Minds Biosciences Inc.

SEC Filings (Chronological Order)

Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.

June 3, 2026	EX-99.3	BRIGHT MINDS BIOSCIENCES INC. 19 Vestry Street New York, NY 10013 MANAGEMENT INFORMATION CIRCULAR (as at February 10, 2026, except as otherwise noted) BRIGHT MINDS BIOSCIENCES INC. 19 Vestry Street New York, NY 10013 MANAGEMENT INFORMATION CIRCULAR (as at February 10, 2026, except as otherwise noted) This Management Information Circular ("Circular") is furnished in connection with the solicitation of proxies by the management of Bright Minds Biosciences Inc. (the "Company") for use at the annual general meeting (the "Meeting") of the Company's s
June 3, 2026	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2026 Commission File No. 001-40997 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2026 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 400 N Aberdeen St Suite 900 Chicago, IL 60642 (U.S. Corporate headquart
June 3, 2026	EX-99.1	BRIGHT MINDS BIOSCIENCES INC. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS BRIGHT MINDS BIOSCIENCES INC. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that the annual general meeting (the "Meeting") of shareholders (the "Shareholders") of Bright Minds Biosciences Inc. (the "Company") will be held at the offices of McMillan LLP, Suite 1500, 1055 West Georgia Street, Vancouver, British Columbia V6E 4N7 on Tuesday, March 31, 2026, at 10:00 a.m. (Pa
June 3, 2026	EX-99.2	BRIGHT MINDS BIOSCIENCES INC. 19 Vestry Street New York, NY 10013 NOTICE AND ACCESS NOTIFICATION TO SHAREHOLDERS ANNUAL GENERAL MEETING OF SHAREHOLDERS BRIGHT MINDS BIOSCIENCES INC. 19 Vestry Street New York, NY 10013 NOTICE AND ACCESS NOTIFICATION TO SHAREHOLDERS ANNUAL GENERAL MEETING OF SHAREHOLDERS You are receiving this notification because Bright Minds Biosciences Inc. (the "Company") has decided to use the notice and access model ("notice and access") for the delivery of meeting materials to its shareholders in respect of its Annual Genera
June 3, 2026	EX-99.4	EXHIBIT 99.4
June 3, 2026	EX-99.5	EXHIBIT 99.5
June 2, 2026	EX-99.1	Date: January 20, 2026 Date: January 20, 2026 To: All Canadian Securities Regulatory Authorities Subject: BRIGHT MINDS BIOSCIENCES INC.
June 2, 2026	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2026 Commission File No. 001-40997 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2026 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 400 N Aberdeen St Suite 900 Chicago, IL 60642 (U.S. Corporate headquarte
May 28, 2026	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2026 Commission File No. 001-40997 BRIG UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2026 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 400 N Aberdeen St Suite 900 Chicago, IL 60642 (U.S. Corporate
May 28, 2026	EX-99.1	Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference FOR IMMEDIATE RELEASE Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference New York City – May 26, 2026 – Bright Minds Biosciences, Inc.
May 20, 2026	EX-99.4	Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ryan Cheung, Chief Financial Officer of Bright Minds Biosciences Inc.
May 20, 2026	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2026 Commission File No. 001-40997 BRIG UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2026 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 400 N Aberdeen St Suite 900 Chicago, IL 60642 (U.S. Corporate headquarters)
May 20, 2026	EX-99.1	Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the six months ended March 31, 2026 and 2025 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the six months ended March 31, 2026 and 2025 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars) March 31, September 30, As at Notes 2026 (unaudited) 2025 (audited) $ $ ASSETS Current Assets Cash and cash equ
May 20, 2026	EX-99.3	Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ian McDonald, Chief Executive Officer of Bright Minds Biosciences Inc.
May 20, 2026	EX-99.2	2 BRIGHT MINDS BIOSCIENCES INC. MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE SECOND QUARTER ENDED MARCH 31, 2026 (All amounts expressed in Canadian dollars, unless otherwise stated) This Management Discussion and Analysis ("MD&A") provides a detailed analysis of the business of Bright Minds Biosciences Inc. (the "Company") and describes the Company's financial results for the second quarter ended Ma
February 13, 2026	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2026 Commission File No. 001-40997 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2026 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 400 N Aberdeen St Suite 900 Chicago, IL 60642 (U.S. Corporate headquart
February 13, 2026	EX-99.3	Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ian McDonald, Chief Executive Officer of Bright Minds Biosciences Inc.
February 13, 2026	EX-99.1	Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three months ended December 31, 2025 and 2024 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three months ended December 31, 2025 and 2024 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars) December 31, September 30, As at Notes 2025 (unaudited) 2025 (audited) $ $ ASSETS Current Assets Cash and
February 13, 2026	EX-99.2	Drug candidate BRIGHT MINDS BIOSCIENCES INC. MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE FIRST QUARTER ENDED DECEMBER 31, 2025 (All amounts expressed in Canadian dollars, unless otherwise stated) This Management Discussion and Analysis ("MD&A") provides a detailed analysis of the business of Bright Minds Biosciences Inc. (the "Company") and describes the Company's financial results for the first quarter ended D
February 13, 2026	EX-99.4	Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ryan Cheung, Chief Financial Officer of Bright Minds Biosciences Inc.
January 9, 2026	424B5	1,945,000 Common Shares BRIGHT MINDS BIOSCIENCES INC. Prospectus Supplement to Prospectus dated September 2, 2025 Filed Pursuant to Rule 424(b)(5) Registration No.
January 9, 2026	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2026 Commission File No. 001-40997 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2026 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 400 N Aberdeen St Suite 900 Chicago, IL 60642 (U.S. Corporate headquarte
January 9, 2026	EX-99.2	Bright Minds Biosciences Inc. Registration Statement on Form F-3 Our File No. 323483 January 7, 2026 The Board of Directors Bright Minds Biosciences Inc. 400 N Aberdeen St Suite 900 Chicago, IL 60642 Dear Sirs: Bright Minds Biosciences Inc. Registration Statement on Form F-3 We have acted as legal counsel to Bright Minds Biosciences Inc., a British Columbia corporation (the "Company"), in connection with the offering (the "Offering") of 1,945,000 common shares,
January 9, 2026	EX-99.1	BRIGHT MINDS BIOSCIENCES ANNOUNCES CLOSING OF US$175 MILLION PUBLIC OFFERING BRIGHT MINDS BIOSCIENCES ANNOUNCES CLOSING OF US$175 MILLION PUBLIC OFFERING New York City, January 9, 2026 - Bright Minds Biosciences Inc.
January 9, 2026	EX-99.1	1,945,000 Common Shares BRIGHT MINDS BIOSCIENCES INC. UNDERWRITING AGREEMENT 1,945,000 Common Shares BRIGHT MINDS BIOSCIENCES INC. UNDERWRITING AGREEMENT January 7, 2026 Jefferies LLC, TD Securities (USA) LLC, Piper Sandler & Co., and Cantor Fitzgerald & Co. As Representatives of the several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, NY 10017 Piper Sandler & Co. 350 North 5th Street Minne
January 9, 2026	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2026 Commission File No. 001-40997 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2026 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 400 N Aberdeen St Suite 900 Chicago, IL 60642 (U.S. Corporate headquarte
January 8, 2026	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2026 Commission File No. 001-40997 UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2026 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 400 N Aberdeen St Suite 900 Chicago, IL 60642 (U.S. Corpor
January 8, 2026	EX-99.1	BRIGHT MINDS BIOSCIENCES ANNOUNCES PRICING OF UPSIZED US$175 MILLION PUBLIC OFFERING OF COMMON STOCK BRIGHT MINDS BIOSCIENCES ANNOUNCES PRICING OF UPSIZED US$175 MILLION PUBLIC OFFERING OF COMMON STOCK New York City, January 7, 2026 - Bright Minds Biosciences Inc.
January 7, 2026	424B5	Subject to Completion, dated January 6, 2026 Common Shares Pre-Funded Warrants to Purchase up to Common Shares Common Shares Underlying the Pre-Funded Warrants BRIGHT MINDS BIOSCIENCES INC. Preliminary Prospectus Supplement to Prospectus dated September 2, 2025 Filed Pursuant to Rule 424(b)(5) Registration No.
January 7, 2026	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2026 Commission File No. 001-40997 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2026 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 400 N Aberdeen St Suite 900 Chicago, IL 60642 (U.S. Corporate headquarte
January 7, 2026	FWP	Important Additional Information Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No.
January 7, 2026	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2026 Commission File No. 001-40997 UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2026 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 400 N Aberdeen St Suite 900 Chicago, IL 60642 (U.S. Corpor
January 7, 2026	EX-99.1	BRIGHT MINDS BIOSCIENCES ANNOUNCES LAUNCH OF US$100 MILLION PUBLIC OFFERING BRIGHT MINDS BIOSCIENCES ANNOUNCES LAUNCH OF US$100 MILLION PUBLIC OFFERING New York City, January 6, 2026 - Bright Minds Biosciences Inc.
January 7, 2026	FWP	Issuer Free Writing Prospectus Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. 333-289851 To Preliminary Prospectus Supplement dated January 6, 2026 (to Prospectus dated September 2, 2025)
January 6, 2026	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2026 Commission File No. 001-40997 UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2026 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 400 N Aberdeen St Suite 900 Chicago, IL 60642 (U.S. Corpor
January 6, 2026	EX-99.1	Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE) For Immediate Release Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE) ·BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability oAbsence: 73.
January 5, 2026	EX-99.1	Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026 – Conference Call and Live Webcast at 8AM ET – For Immediate Release Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026 – Conference Call and Live Webcast at 8AM ET – - NEW YORK CITY and VANCOUVER, British Columbia, January 5, 2026 – Bright Minds Biosciences Inc.
January 5, 2026	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2026 Commission File No. 001-40997 UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2026 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 400 N Aberdeen St Suite 900 Chicago, IL 60642 (U.S. Corpor
December 23, 2025	EX-99.6	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.6 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Bright Minds Biosciences Inc. on Form 40-F for the fiscal year ended September 30, 2025 filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certify that to the best of our
December 23, 2025	EX-99.4	CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.4 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ian McDonald, certify that: 1. I have reviewed this Annual Report on Form 40-F of Bright Minds Biosciences Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i
December 23, 2025	EX-99.3	Drug candidate Exhibit 99.3 BRIGHT MINDS BIOSCIENCES INC. MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE FOURTH QUARTER ENDED SEPTEMBER 30, 2025 (All amounts expressed in Canadian dollars, unless otherwise stated) This Management Discussion and Analysis (“MD&A”) provides a detailed analysis of the business of Bright Minds Biosciences Inc. (the “Company”) and describes the Company’s financial results for the fourth
December 23, 2025	EX-99.2	Bright Minds Biosciences Inc. Consolidated Financial Statements For the years ended September 30, 2025, 2024, and 2023 (Expressed in Canadian Dollars) REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 99.2 Bright Minds Biosciences Inc. Consolidated Financial Statements For the years ended September 30, 2025, 2024, and 2023 (Expressed in Canadian Dollars) REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Shareholders of Bright Minds Biosciences Inc. Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated statement
December 23, 2025	F-X	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-X APPOINTMENT OF AGENT FOR SERVICE OF PROCESS AND UNDERTAKING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-X APPOINTMENT OF AGENT FOR SERVICE OF PROCESS AND UNDERTAKING A. Name of issuer or person filing (“Filer”): Bright Minds Biosciences Inc. B. (1) This is [check one]: ☒ an original filing for the Filer. ☐ an amended filing for the Filer. (2) Check the following box if you are filing the Form F-X in paper in accordance wi
December 23, 2025	EX-99.8	CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 99.8 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the use of our report dated December 23, 2025 on the consolidated statements of financial position of Bright Minds Biosciences Inc. (the “Company”) as of September 30, 2025 and 2024, and the related consolidated statements of comprehensive loss, changes in shareholders’ equity and cash flows for the years en
December 23, 2025	EX-99.5	CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.5 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ryan Cheung, certify that: 1. I have reviewed this Annual Report on Form 40-F of Bright Minds Biosciences Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
December 23, 2025	EX-99.1	BRIGHT MINDS BIOSCIENCES INC. ANNUAL INFORMATION FORM For the Fiscal Year Ended September 30, 2025 Dated December 23, 2025 Exhibit 99.1 BRIGHT MINDS BIOSCIENCES INC. ANNUAL INFORMATION FORM For the Fiscal Year Ended September 30, 2025 Dated December 23, 2025 TABLE OF CONTENTS INTRODUCTORY NOTES 3 Introduction 3 Date of Information 3 Currency and Exchange Rates 3 Use of Market and Industry Data 3 FORWARD-LOOKING INFORMATION 3 GLOSSARY OF TERMS 8 CORPORATE STRUCTURE 11 Name, Address and Incorporation 11 Intercorporate R
December 23, 2025	40-F	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 40-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 40-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13(a) OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2025 Commission File Number: 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Exact name of Registrant as
November 17, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission File No. 001-40997 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive of
November 17, 2025	6-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A Amendment No. 1 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A Amendment No. 1 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of prin
November 17, 2025	EX-99.1	BRIGHT MINDS BIOSCIENCES EXPANDS SCIENTIFIC ADVISORY BOARD TO INCLUDE RENOWNED EXPERTS IN PRADER-WILLI SYNDROME (PWS) -- Tania Markovic MBBS PhD FRACP; Jennifer L. Miller, MD; Elizabeth Roof, H.S.P., M.A.; and Theresa V. Strong, PhD; distinguished gl FOR IMMEDIATE RELEASE BRIGHT MINDS BIOSCIENCES EXPANDS SCIENTIFIC ADVISORY BOARD TO INCLUDE RENOWNED EXPERTS IN PRADER-WILLI SYNDROME (PWS) - Tania Markovic MBBS PhD FRACP; Jennifer L.
November 17, 2025	EX-99.1	BRIGHT MINDS BIOSCIENCES INITIATES NEW PRADER-WILLI SYNDROME (PWS) PROGRAM; KOL EVENT SCHEDULED FOR NOVEMBER 6TH -- Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and tolerability FOR IMMEDIATE RELEASE BRIGHT MINDS BIOSCIENCES INITIATES NEW PRADER-WILLI SYNDROME (PWS) PROGRAM; KOL EVENT SCHEDULED FOR NOVEMBER 6TH - Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and tolerability of BMB-101 (NOVA Study) for the treatment of patients with Prader-Willi Syndrome - - Key Opinion Leaders (KOLs) participating on the call will include Theresa V.
November 7, 2025	EX-99.1	Bright Minds Biosciences to Present at Upcoming Conferences For Immediate Release Bright Minds Biosciences to Present at Upcoming Conferences New York City - October 30, 2025 - Bright Minds Biosciences, Inc.
November 7, 2025	EX-99.1	BRIGHT MINDS BIOSCIENCES INITIATES NEW PRADER-WILLI SYNDROME (PWS) PROGRAM; KOL EVENT SCHEDULED FOR NOVEMBER 6TH -- Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and tolerability FOR IMMEDIATE RELEASE BRIGHT MINDS BIOSCIENCES INITIATES NEW PRADER-WILLI SYNDROME (PWS) PROGRAM; KOL EVENT SCHEDULED FOR NOVEMBER 6TH - Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and tolerability of BMB-101 (NOVA Study) for the treatment of patients with Prader-Willi Syndrome - - Key Opinion Leaders (KOLs) participating on the call will include Theresa V.
November 7, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2025 Commission File No. 001-40997 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive off
November 7, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission File No. 001-40997 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive of
September 5, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission File No. 001-4099 UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of princip
September 5, 2025	EX-99.1	Bright Minds Biosciences Announces BMB‑201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model For Immediate Release Bright Minds Biosciences Announces BMB‑201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model New York, New York — September 4, 2025 — Bright Minds Biosciences Inc.
September 2, 2025	EFFECT	EFFECT X0101 EFFECT 33 LIVE 2025-09-02 16:15:00 F-3 0001827401 BRIGHT MINDS BIOSCIENCES INC. 333-289851
August 28, 2025	CORRESP	Bright Minds Biosciences Inc. (the "Company") Registration Statement on Form F-3 filed August 26, 2025 File No. 333-289851 Acceleration Request for Registration Statement VIA EDGAR Correspondence August 28, 2025 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
August 27, 2025	LETTER	LETTER August 27, 2025 Ian McDonald Chief Executive Officer Bright Minds Biosciences Inc.
August 26, 2025	EX-FILING FEES	Security Type Calculation of Filing Fee Tables F-3 BRIGHT MINDS BIOSCIENCES INC. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forwa
August 26, 2025	EX-1.2	BRIGHT MINDS BIOSCIENCES INC. EQUITY DISTRIBUTION AGREEMENT BRIGHT MINDS BIOSCIENCES INC. EQUITY DISTRIBUTION AGREEMENT August 25, 2025 PIPER SANDLER & CO. 350 North 5th Street, Suite 1000 Minneapolis, MN 55401 CANTOR FITZGERALD & CO. 110 East 59th Street New York, New York 10022 Ladies and Gentlemen: As further set forth in this agreement (this "Agreement"), Bright Minds Biosciences Inc., a company organized under the laws of the Province of British Colum
August 26, 2025	F-3	As filed with the Securities and Exchange Commission on August 25, 2025 As filed with the Securities and Exchange Commission on August 25, 2025 Registration No.
August 15, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File No. 001-40997 B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offi
August 15, 2025	EX-99.2	2 BRIGHT MINDS BIOSCIENCES INC. MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE THIRD QUARTER ENDED JUNE 30, 2025 (All amounts expressed in Canadian dollars, unless otherwise stated) This Management Discussion and Analysis ("MD&A") provides a detailed analysis of the business of Bright Minds Biosciences Inc. (the "Company") and describes the Company's financial results for the third quarter ended June
August 15, 2025	EX-99.1	Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the nine months ended June 30, 2025 and 2024 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the nine months ended June 30, 2025 and 2024 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars) June 30, September 30, As at Notes 2025 (unaudited) 2024 (audited) $ $ ASSETS Current Assets Cash and cash equi
August 15, 2025	EX-99.3	Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ian McDonald, Chief Executive Officer of Bright Minds Biosciences Inc.
August 15, 2025	EX-99.4	Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ryan Cheung, Chief Financial Officer of Bright Minds Biosciences Inc.
August 11, 2025	EX-99.3	Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ian McDonald, Chief Executive Officer of Bright Minds Biosciences Inc.
August 11, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File No. 001-40997 BRIG UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive office)
August 11, 2025	EX-99.1	Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the six months ended March 31, 2025 and 2024 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the six months ended March 31, 2025 and 2024 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars) March 31, September 30, As at Notes 2025 (unaudited) 2024 (audited) $ $ ASSETS Current Assets Cash and cash equ
August 11, 2025	EX-99.2	2 BRIGHT MINDS BIOSCIENCES INC. MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE SECOND QUARTER ENDED MARCH 31, 2025 (All amounts expressed in Canadian dollars, unless otherwise stated) This Management Discussion and Analysis ("MD&A") provides a detailed analysis of the business of Bright Minds Biosciences Inc. (the "Company") and describes the Company's financial results for the second quarter ended Ma
August 11, 2025	EX-99.4	Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ryan Cheung, Chief Financial Officer of Bright Minds Biosciences Inc.
May 28, 2025	EX-99.1	Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference FOR IMMEDIATE RELEASE Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference New York and Vancouver, BC – May 28, 2025 – Bright Minds Biosciences, Inc.
May 28, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File No. 001-40997 BRIG UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive office)
May 21, 2025	EX-99.1	Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025 - Key Opinion Leaders (KOLs) on Absence seizures include Dennis Dlugos, MD, Wendyl D’Souza, MBChB, MPH, FRACP, PhD, and Alexander Rotenberg, FOR IMMEDIATE RELEASE Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025 - Key Opinion Leaders (KOLs) on Absence seizures include Dennis Dlugos, MD, Wendyl D’Souza, MBChB, MPH, FRACP, PhD, and Alexander Rotenberg, MD, PhD - Vancouver, British Columbia, May 20, 2025 - Bright Minds Biosciences Inc.
May 21, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File No. 001-40997 BRIG UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal exe
May 14, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File No. 001-40997 BRIG UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal exe
May 14, 2025	EX-99.1	Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101 FOR IMMEDIATE RELEASE Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101 -BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model - -The DBA/2 model is highly predictive of sudden unexpected death in epilepsy (SUDEP) - -Findings highlight BMB-101’s potential to address critical gaps in SUDEP prevention - New York and Vancouver, British Columbia, May 13, 2025 - Bright Minds Biosciences Inc.
April 29, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File No. 001-40997 BR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offic
April 29, 2025	EX-99.1	Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study FOR IMMEDIATE RELEASE Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study Vancouver, British Columbia, April 28, 2025 - Bright Minds Biosciences Inc.
March 5, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File No. 001-40997 BR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offic
March 5, 2025	EX-99.1	Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research -- Dennis Dlugos, MD, MSCE; Jacqueline French, MD; Terrence O'Brien, MD; Jo Sourbron, MD, PhD, MPharm; and Joseph Sullivan, MD, bring decades FOR IMMEDIATE RELEASE Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research - Dennis Dlugos, MD, MSCE; Jacqueline French, MD; Terrence O'Brien, MD; Jo Sourbron, MD, PhD, MPharm; and Joseph Sullivan, MD, bring decades of experience in epilepsy drug development and research to support Company’s clinical focus on epilepsy – Vancouver, British Columbia, March 4, 2025 - Bright Minds Biosciences Inc.
February 24, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File No. 001-40997 UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principa
February 24, 2025	EX-99.1	Bright Minds Biosciences to Participate at Three Healthcare Conferences in March Bright Minds Biosciences to Participate at Three Healthcare Conferences in March New York and Vancouver, BC – February 24, 2025 – Bright Minds Biosciences, Inc.
February 14, 2025	424B3	BRIGHT MINDS BIOSCIENCES INC. 1,612,902 Common Shares Filed Pursuant to Rule 424(b)(3) Registration No. 333-284694 Prospectus BRIGHT MINDS BIOSCIENCES INC. 1,612,902 Common Shares This prospectus relates to the resale of up to 1,612,902 common shares (the "Common Shares") of Bright Minds Biosciences Inc. (the "Company") that may be offered and sold, from time to time, by the selling securityholders identified in this prospectus. These shares consist
February 14, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File No. 001-40997 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive of
February 14, 2025	EX-99.3	Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ian McDonald, Chief Executive Officer of Bright Minds Biosciences Inc.
February 14, 2025	EX-99.1	Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three months ended December 31, 2024 and 2023 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three months ended December 31, 2024 and 2023 (Expressed in Canadian Dollars) 1 \| Page Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars) December 31, September 30, As at Notes 2024 (unaudited) 2024 (audited) $ $ ASSETS Current Assets
February 14, 2025	EX-99.4	Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ryan Cheung, Chief Financial Officer of Bright Minds Biosciences Inc.
February 14, 2025	EX-99.2	Studies Completed & Other Milestones Accomplished: BRIGHT MINDS BIOSCIENCES INC. MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE FIRST QUARTER ENDED DECEMBER 31, 2024 (All amounts expressed in Canadian dollars, unless otherwise stated) This Management Discussion and Analysis ("MD&A") provides a detailed analysis of the business of Bright Minds Biosciences Inc. (the "Company") and describes the Company's financial results for the first quarter ended D
February 12, 2025	CORRESP	Bright Minds Biosciences Inc. (the "Company") Registration Statement on Form F-3 filed February 5, 2025 File No. 333-284694 Acceleration Request for Registration Statement VIA EDGAR Correspondence February 12, 2025 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
February 11, 2025	LETTER	LETTER February 11, 2025 Ian McDonald Chief Executive Officer Bright Minds Biosciences Inc.
February 5, 2025	EX-10.1	COMMON SHARE SUBSCRIPTION AGREEMENT CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL COMMON SHARE SUBSCRIPTION AGREEMENT TO: Bright Minds Biosciences Inc.
February 5, 2025	EX-FILING FEES	Calculation of Filing Fee Tables FORM F-3 (Form Type) BRIGHT MINDS BIOSCIENCES INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Exhibit 107 Calculation of Filing Fee Tables FORM F-3 (Form Type) BRIGHT MINDS BIOSCIENCES INC.
February 5, 2025	F-3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BRIGHT MINDS BIOSCIENCES INC. (Exact name of registrant as specified in its charter) British Columbia (State or o UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BRIGHT MINDS BIOSCIENCES INC. (Exact name of registrant as specified in its charter) British Columbia (State or other jurisdiction of incorporation or organization) N/A (I.R.S. Employer Identification Number) 19 Vestry Street, New York, NY 10013 (604) 689-9111 (A
January 8, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File No. 001-40997 UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal
January 8, 2025	EX-99.1	Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer -- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer - Dr. Collins brings extensive drug development and clinical expertise in epilepsy - New York and Vancouver, BC – January 7, 2025 – Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 ag
December 31, 2024	EX-4.4	BRIGHT MINDS BIOSCIENCES INC. INDEPENDENT CONTRACTOR AGREEMENT 1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
December 31, 2024	EX-2.2	DESCRIPTION OF REGISTRANT'S SECURITIES EXHIBIT 2.2 DESCRIPTION OF REGISTRANT'S SECURITIES The following securities of our Company are registered under section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"): our Company's common shares are listed on the Nasdaq Capital Market ("Nasdaq"), under the symbol "DRUG". Jurisdiction of Incorporation Our Company was incorporated under the Business Corporations Act (
December 31, 2024	EX-15.6	BRIGHT MINDS BIOSCIENCES INC. (the "Corporation") CYBERSECURITY POLICY BRIGHT MINDS BIOSCIENCES INC. (the "Corporation") CYBERSECURITY POLICY Purpose The Board of Directors of the Corporation has adopted this Cybersecurity Policy (or the "Policy" as the context provides for) with a purpose of serving as a standard for setting, reviewing and implementing the Corporation's cybersecurity goals, objectives and targets. The "Corporation" includes Bright Minds Biosciences
December 31, 2024	20-F	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE AC
December 31, 2024	EX-12.1	CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 12.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ian McDonald, certify that: 1. I have reviewed this Annual Report on Form 20-F of Bright Minds Biosciences Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i
December 31, 2024	EX-12.2	CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 12.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ryan Cheung, certify that: 1. I have reviewed this Annual Report on Form 20-F of Bright Minds Biosciences Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
December 31, 2024	EX-15.5	BRIGHT MINDS BIOSCIENCES INC. (the "Corporation") INSIDER TRADING, REPORTING AND BLACKOUT POLICY BRIGHT MINDS BIOSCIENCES INC. (the "Corporation") INSIDER TRADING, REPORTING AND BLACKOUT POLICY This Insider Trading, Reporting and Blackout Policy (the "Policy") should be read in conjunction with each of the Corporation's current Securities Trading and Reporting Guidelines and Corporate Disclosure Policy. Purpose The purpose of this Policy is to further explain certain legal concepts with respe
December 31, 2024	EX-13.1	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Bright Minds Biosciences Inc. on Form 20-F for the fiscal year ended September 30, 2024 filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certify that to the best of our
November 21, 2024	EX-99.1	Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting - Poster presentations on BMB-101 will focus on 5-HT2C functional selectivity and Phase 1 clinical data - For Immediate Release Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting - Poster presentations on BMB-101 will focus on 5-HT2C functional selectivity and Phase 1 clinical data - NEW YORK, November 21, 2024 - Bright Minds Biosciences Inc.
November 21, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File No. 001-40997 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive of
November 12, 2024	EX-99.1	AGREEMENT EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of November 12, 2024 is by and among RA Capital Management, L.
November 12, 2024	SC 13G	DRUG / Bright Minds Biosciences Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment SC 13G 1 tm2427451d4sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Bright Minds Biosciences Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 10919W405 (CUSIP Number) November 4, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to
November 6, 2024	SC 13G/A	DRUG / Bright Minds Biosciences Inc. / Cormorant Asset Management, LP - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Bright Minds Biosciences Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 10919W405 (CUSIP Number) November 4, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic
November 5, 2024	EX-99.1	BRIGHT MINDS BIOSCIENCES CLOSES US$35 MILLION NON-BROKERED PRIVATE PLACEMENT BRIGHT MINDS BIOSCIENCES CLOSES US$35 MILLION NON-BROKERED PRIVATE PLACEMENT Vancouver, British Columbia, November 4, 2024 - Bright Minds Biosciences Inc.
November 5, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File No. 001-40997 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive of
November 5, 2024	SC 13D/A	DRUG / Bright Minds Biosciences Inc. / McDonald Ian - FORM SC 13D/A Activist Investment SC 13D/A 1 formsc13da.htm FORM SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 4)* Under the Securities Exchange Act of 1934 BRIGHT MINDS BIOSCIENCES INC. (Name of Issuer) COMMON STOCK, WITHOUT PAR VALUE (Title of Class of Securities) 10919W405 (CUSIP Number) Ian McDonald Park Towers B804, DIFC Dubai, United Arab Emirates (Name, Addres
November 5, 2024	SC 13D/A	DRUG / Bright Minds Biosciences Inc. / McDonald Ian - FORM SC 13D/A Activist Investment SC 13D/A 1 formsc13da.htm FORM SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 3)* Under the Securities Exchange Act of 1934 BRIGHT MINDS BIOSCIENCES INC. (Name of Issuer) COMMON STOCK, WITHOUT PAR VALUE (Title of Class of Securities) 10919W405 (CUSIP Number) Ian McDonald Park Towers B804, DIFC Dubai, United Arab Emirates (Name, Addres
October 25, 2024	SC 13G	DRUG / Bright Minds Biosciences Inc. / COMMODORE CAPITAL LP Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* BRIGHT MINDS BIOSCIENCES INC. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 10919W405 (CUSIP Number) October 18, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box
October 23, 2024	SC 13G	DRUG / Bright Minds Biosciences Inc. / Point72 Asset Management, L.P. - BRIGHT MINDS BIOSCIENCES INC. Passive Investment SC 13G 1 p24-2994sc13g.htm BRIGHT MINDS BIOSCIENCES INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Bright Minds Biosciences Inc. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 10919W405 (CUSIP Number) October 16, 2024 (Date of Event Which Requires Filing of this Statement) Che
October 23, 2024	SC 13G	DRUG / Bright Minds Biosciences Inc. / Logos Global Management LP Passive Investment SC 13G 1 drug13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Bright Minds Biosciences Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 10919W405 (CUSIP Number) October 16, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru
October 23, 2024	EX-99.1	JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p24-2994exhibit991.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing
October 22, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 tm2426599d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Bright Minds Biosciences Inc., a Canadian corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange
October 22, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of October 22, 2024, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the “Filers”). Each of the Filers may be required to file with
October 22, 2024	SC 13G/A	DRUG / Bright Minds Biosciences Inc. / PFM Health Sciences, LP - SC 13G/A Passive Investment SC 13G/A 1 tm2426599d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Bright Minds Biosciences Inc. (Name of Issuer) Common Shares, Without Par Value (Title of Class of Securities) 10919W405 (CUSIP Number) Octob
October 22, 2024	SC 13G	DRUG / Bright Minds Biosciences Inc. / Cormorant Asset Management, LP Passive Investment SC 13G 1 sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Bright Minds Biosciences Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 10919W405 (CUSIP Number) October 15, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul
October 21, 2024	EX-99.1	Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data NEW YORK AND VANCOUVER, October 21, 2024 – Bright Minds Biosciences Inc.
October 21, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File No. 001-40997 UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal
October 18, 2024	EX-99.1	NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES BRIGHT MINDS BIOSCIENCES ANNOUNCES US$35 MILLION NON-BROKERED PRIVATE NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES BRIGHT MINDS BIOSCIENCES ANNOUNCES US$35 MILLION NON-BROKERED PRIVATE PLACEMENT Vancouver, British Columbia, October 18, 2024 - Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) i
October 18, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File No. 001-40997 UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal
October 16, 2024	EX-99.1	Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models EXHIBIT 99.1 Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models BMB-201 demonstrated dose-dependent efficacy in pain models BMB-201 demonstrated similar efficacy to morphine in several pain models NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) - Bright Minds Biosciences Inc. (NASDAQ: DRUG), a pioneering co
October 16, 2024	EX-99.1	AGREEMENT EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: October 16, 2024 PERCEPTIVE ADVISORS LLC B
October 16, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-40 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-40997 Bright Minds Biosciences Inc. (Translation of registrant's name into English) 19 Vestry Street New York, NY 10013 (Address of principal executive
October 16, 2024	EX-99.1	UNAWARE OF ANY MATERIAL CHANGES UNAWARE OF ANY MATERIAL CHANGES Vancouver, British Columbia, October 15, 2024 – At the request of CIRO, Bright Minds Biosciences Inc.
October 16, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File No. 001-40997 UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal
October 16, 2024	SC 13G	DRUG / Bright Minds Biosciences Inc. / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Bright Minds Biosciences Inc (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 10919W405 (CUSIP Number) October 14, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
October 3, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-40 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-40997 Bright Minds Biosciences Inc. (Translation of registrant's name into English) 19 Vestry Street New York, NY 10013 (Address of principal executive
October 3, 2024	EX-99.1	Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events EXHIBIT 99.1 Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events Bright Minds Biosciences will present scientific posters about various programs in development, including BMB-101, BMB-201 and BMB-202 Bright Minds Biosciences will participate in BIO Europe partnering event and Chicago Biocapital Summit to present its innovation in neuroscience N
September 12, 2024	EX-99.1	Bright Minds Biosciences Initiates Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy ·Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs ·BMB-101 is a novel highly selective 5-HT2C agonist.
September 12, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File No. 001-4099 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive o
August 15, 2024	EX-99.2	Studies Completed & Other Milestones Accomplished: BRIGHT MINDS BIOSCIENCES INC. MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE THIRD QUARTER ENDED JUNE 30, 2024 (All amounts expressed in Canadian dollars, unless otherwise stated) This Management Discussion and Analysis ("MD&A") provides a detailed analysis of the business of Bright Minds Biosciences Inc. (the "Company") and describes the Company's financial results for the third quarter ended June
August 15, 2024	EX-99.4	Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ryan Cheung, Chief Financial Officer of Bright Minds Biosciences Inc.
August 15, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File No. 001-40997 B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offi
August 15, 2024	EX-99.1	Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the nine months ended June 30, 2024 and 2023 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the nine months ended June 30, 2024 and 2023 (Expressed in Canadian Dollars) 1 \| P a g e Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars - Unaudited) June 30, September 30, As at Notes 2024 (unaudited) 2023 (audited) $ $ ASSETS Current A
August 15, 2024	EX-99.3	Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ian McDonald, Chief Executive Officer of Bright Minds Biosciences Inc.
May 17, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File No. 001-40997 BRIG UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive office)
May 17, 2024	EX-99.2	BRIGHT MINDS BIOSCIENCES INC. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS BRIGHT MINDS BIOSCIENCES INC. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that the annual general meeting (the "Meeting") of shareholders (the "Shareholders") of Bright Minds Biosciences Inc. (the "Company") will be held at the offices of McMillan LLP, Suite 1500, 1055 West Georgia Street, Vancouver, British Columbia V6E 4N7 on Friday, March 22, 2024, at 10:00 a.m. (Pac
May 17, 2024	EX-99.1	Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the six months ended March 31, 2024 and 2023 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the six months ended March 31, 2024 and 2023 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars) March 31, September 30, As at Notes 2024 (unaudited) 2023 (audited) $ $ ASSETS Current Assets Cash and cash equ
May 17, 2024	EX-99.3	BRIGHT MINDS BIOSCIENCES INC. 19 Vestry Street New York, NY 10013 MANAGEMENT INFORMATION CIRCULAR (as at February 5, 2024, except as otherwise noted) BRIGHT MINDS BIOSCIENCES INC. 19 Vestry Street New York, NY 10013 MANAGEMENT INFORMATION CIRCULAR (as at February 5, 2024, except as otherwise noted) This Management Information Circular ("Circular") is furnished in connection with the solicitation of proxies by the management of Bright Minds Biosciences Inc. (the "Company") for use at the annual general meeting (the "Meeting") of the Company's sh
May 17, 2024	EX-99.4	Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ryan Cheung, Chief Financial Officer of Bright Minds Biosciences Inc.
May 17, 2024	EX-99.5	EX-99.5
May 17, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File No. 001-40997 BR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offic
May 17, 2024	EX-99.6	NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES BRIGHT MINDS BIOSCIENCES ANNOUNCES RESULTS OF AGM NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES BRIGHT MINDS BIOSCIENCES ANNOUNCES RESULTS OF AGM Vancouver, British Columbia, March 27, 2024 - Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company"), a leading biotechnology company
May 17, 2024	EX-99.1	Date: January 11, 2024 510 Burrard St, 3rd Floor Vancouver BC, V6C 3B9 www.computershare.com Date: January 11, 2024 To: All Canadian Securities Regulatory Authorities Subject: BRIGHT MINDS BIOSCIENCES INC. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type: Annual General Meeting Record Date for Notice of Meeting: February 05, 2024 Rec
May 17, 2024	EX-99.3	Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ian McDonald, Chief Executive Officer of Bright Minds Biosciences Inc.
May 17, 2024	EX-99.4	EX-99.4
May 17, 2024	EX-99.2	Studies Completed & Other Milestones Accomplished: BRIGHT MINDS BIOSCIENCES INC. MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE SECOND QUARTER ENDED MARCH 31, 2024 (All amounts expressed in Canadian dollars, unless otherwise stated) This Management Discussion and Analysis ("MD&A") provides a detailed analysis of the business of Bright Minds Biosciences Inc. (the "Company") and describes the Company's financial results for the second quarter ended Ma
February 26, 2024	SC 13D/A	DRUG / Bright Minds Biosciences Inc. / McDonald Ian Activist Investment SC 13D/A 1 sc13da2-im.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* BRIGHT MINDS BIOSCIENCES INC. (Name of Issuer) COMMON STOCK, WITHOUT PAR VALUE (Title of Class of Securities) 10919W405 (CUSIP Number) Ian McDonald Park Towers B804, DIFC Dubai, United Arab Emirates (Name, Address and Telephone
February 26, 2024	SC 13D/A	DRUG / Bright Minds Biosciences Inc. / McDonald Ian Activist Investment SC 13D/A 1 sc13da1-im.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* BRIGHT MINDS BIOSCIENCES INC. (Name of Issuer) COMMON STOCK, WITHOUT PAR VALUE (Title of Class of Securities) 10919W405 (CUSIP Number) Ian McDonald Park Towers B804, DIFC, Dubai, UAE (Name, Address and Telephone Number of Person
February 13, 2024	EX-99.4	Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ryan Cheung, Chief Financial Officer of Bright Minds Biosciences Inc.
February 13, 2024	EX-99.1	Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three months ended December 31, 2023 and 2022 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three months ended December 31, 2023 and 2022 (Expressed in Canadian Dollars) 1 \| Page Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars) December 31, September 30, As at Notes 2023 (unaudited) 2023 (audited) $ $ ASSETS Current Assets
February 13, 2024	EX-99.3	Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ian McDonald, Chief Executive Officer of Bright Minds Biosciences Inc.
February 13, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File No. 001-40997 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive of
February 13, 2024	EX-99.2	Studies Completed & Other Milestones Accomplished: BRIGHT MINDS BIOSCIENCES INC. MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE FIRST QUARTER ENDED DECEMBER 31, 2023 (All amounts expressed in Canadian dollars, unless otherwise stated) This Management Discussion and Analysis ("MD&A") provides a detailed analysis of the business of Bright Minds Biosciences Inc. (the "Company") and describes the Company's financial results for the first quarter ended D
January 18, 2024	SC 13D	DRUG / Bright Minds Biosciences Inc. / McDonald Ian Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 BRIGHT MINDS BIOSCIENCES INC. (Name of Issuer) COMMON STOCK, WITHOUT PAR VALUE (Title of Class of Securities) 10919W405 (CUSIP Number) Ian McDonald 560 King Street West Toronto, Ontario, Canada, M5V 0L5 (Name, Address and Telephone Number of Person Authorized to Receive No
December 29, 2023	EX-12.1	CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 12.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ian McDonald, certify that: 1. I have reviewed this Annual Report on Form 20-F of Bright Minds Biosciences Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i
December 29, 2023	EX-97.1	BRIGHT MINDS BIOSCIENCES INC. POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED INCENTIVE-BASED COMPENSATION (the "Recovery Policy") As adopted by the Board of Directors on December 1, 2023 BRIGHT MINDS BIOSCIENCES INC. POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED INCENTIVE-BASED COMPENSATION (the "Recovery Policy") As adopted by the Board of Directors on December 1, 2023 1. GENERAL PROVISIONS Purpose (a) This Recovery Policy has been adopted by resolution of the Board (as hereinafter defined) in accordance with certain listing standards of the Nasdaq Stock Market LLC mandated by S
December 29, 2023	EX-12.2	CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 12.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ryan Cheung, certify that: 1. I have reviewed this Annual Report on Form 20-F of Bright Minds Biosciences Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
December 29, 2023	EX-2.2	DESCRIPTION OF REGISTRANT'S SECURITIES EXHIBIT 2.2 DESCRIPTION OF REGISTRANT'S SECURITIES The following securities of our Company are registered under section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"): our Company's common shares are listed on the Nasdaq Capital Market ("Nasdaq"), under the symbol "DRUG". Jurisdiction of Incorporation Our Company was incorporated under the Business Corporations Act (
December 29, 2023	EX-13.1	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Bright Minds Biosciences Inc. on Form 20-F for the fiscal year ended September 30, 2023 filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certify that to the best of our
December 29, 2023	EX-2.1	EX-2.1
December 29, 2023	EX-16.1	BRIGHT MINDS BIOSCIENCES INC. (the "Corporation") SECURITIES TRADING AND REPORTING GUIDELINES BRIGHT MINDS BIOSCIENCES INC. (the "Corporation") SECURITIES TRADING AND REPORTING GUIDELINES These Securities Trading and Reporting Guidelines (the "Guidelines") are to be read in conjunction with the Corporation's Corporate Disclosure Policy. Objectives The Corporation's commitment to ethical and lawful business conduct is a fundamental shared value of the Corporation's Board of Directors (the "
December 29, 2023	20-F	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE AC
December 26, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File No. 001-40997 UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principa
December 26, 2023	EX-99.1	Bright Minds Announces Closing of Non-Brokered Private Placement Fully Subscribed by Management Bright Minds Announces Closing of Non-Brokered Private Placement Fully Subscribed by Management Vancouver, British Columbia, December 22, 2023 – Bright Minds Biosciences Inc.
December 8, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File No. 001-40997 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive of
December 8, 2023	EX-99.1	NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES Bright Minds Announces Non-Brokered Private Placement Fully Subscribed NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management Vancouver, British Columbia, December 6, 2023 - Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Compan
August 15, 2023	EX-99.1	Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three and nine months ended June 30, 2023 and 2022 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three and nine months ended June 30, 2023 and 2022 (Expressed in Canadian Dollars) 1 \| Page Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars) June 30, September 30, As at Notes 2023 (unaudited) 2022 (audited) $ $ ASSETS Current Assets
August 15, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File No. 001-40997 B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offi
August 15, 2023	EX-99.3	Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ian McDonald, Chief Executive Officer of Bright Minds Biosciences Inc.
August 15, 2023	EX-99.2	Studies Completed & Other Milestones Accomplished: BRIGHT MINDS BIOSCIENCES INC. MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE THIRD QUARTER ENDED JUNE 30, 2023 (All amounts expressed in Canadian dollars, unless otherwise stated) This Management Discussion and Analysis ("MD&A") provides a detailed analysis of the business of Bright Minds Biosciences Inc. (the "Company") and describes the Company's financial results for the third quarter ended June
August 15, 2023	EX-99.4	Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ryan Cheung, Chief Financial Officer of Bright Minds Biosciences Inc.
August 8, 2023	EX-99.1	Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101 -- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of For Immediate Release Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101 - BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders - qEEG study was conduct
August 8, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File No. 001-40997 B UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal
July 20, 2023	EX-99.1	Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101 -- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other in For Immediate Release Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101 - BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders - BMB-101 demonstrated an excellent safety and tolerability profile in single ascending dose, multiple ascending dose and food effects study - BMB-101 demonstrated central target engagement and predictable plasma pharmacokinetics Vancouver, British Columbia, July 20, 2023 – Bright Minds Biosciences Inc.
July 20, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File No. 001-40997 BRI UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal ex
July 12, 2023	EX-99.1	Bright Minds Announces Effective Date of Share Consolidation Bright Minds Announces Effective Date of Share Consolidation Vancouver, British Columbia, July 11, 2023 – Bright Minds Biosciences Inc.
July 12, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File No. 001-40997 BRI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive office
June 22, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File No. 001-40997 BRI UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal ex
June 22, 2023	EX-99.1	Bright Minds Announces Proposed Share Consolidation Bright Minds Announces Proposed Share Consolidation Vancouver, British Columbia, June 22, 2023 – Bright Minds Biosciences Inc.
May 15, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File No. 001-40997 BRIG UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive office)
May 15, 2023	EX-99.1	Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three and six months ended March 31, 2023 and 2022 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three and six months ended March 31, 2023 and 2022 (Expressed in Canadian Dollars) 1 \| Page Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars) March 31, September 30, As at Notes 2023 (unaudited) 2022 (audited) $ $ ASSETS Current Asset
May 15, 2023	EX-99.4	Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ryan Cheung, Chief Financial Officer of Bright Minds Biosciences Inc.
May 15, 2023	EX-99.3	Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ian McDonald, Chief Executive Officer of Bright Minds Biosciences Inc.
May 15, 2023	EX-99.2	Studies Completed & Other Milestones Accomplished: BRIGHT MINDS BIOSCIENCES INC. MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE SECOND QUARTER ENDED MARCH 31, 2023 (All amounts expressed in Canadian dollars, unless otherwise stated) This Management Discussion and Analysis ("MD&A") provides a detailed analysis of the business of Bright Minds Biosciences Inc. (the "Company") and describes the Company's financial results for the second quarter ended Ma
April 19, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File No. 001-40997 BR UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal e
April 19, 2023	EX-99.1	Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202 -- BMB-202 is the first clinical candidate from an extensive portfolio of selective 5-HT2A and 5-HT2A/2C agonists inspired from natur For Immediate Release Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202 - BMB-202 is a highly selective 5-HT2A agonist that exhibits a more than 30-fold selectivity over 5-HT2C and more than 500-fold selectivity over 5-HT2B – - BMB-202 is the first clinical candidate from an extensive portfolio of selective 5-HT2A and 5-HT2A/2C agonists inspired from natural compound scaffolds – Vancouver, British Columbia, April 19, 2023 – Bright Minds Biosciences Inc.
April 10, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-4099 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-40997 Bright Minds Biosciences Inc. (Translation of registrant's name into English) 19 Vestry Street New York, NY 10013 (Address of principal executive of
April 10, 2023	EX-99.1	Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research — Presentation entitled "BMB-101: A selective 5-HT2C agonist in clinical trials with therapeutic utility" — — First-in-human Pha EXHIBIT 99.1 Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research — Presentation entitled "BMB-101: A selective 5-HT2C agonist in clinical trials with therapeutic utility" — — First-in-human Phase 1 trial for lead program, BMB-101, is underway in Australia — VANCOUVER, British Columbia, April 10, 2023 (GLOBE NEWSWIRE) - Bright Mi
March 2, 2023	EX-99.4	Financial Statement Request Form
March 2, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File No. 001-40997 BR UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal e
March 2, 2023	EX-99.2	BRIGHT MINDS BIOSCIENCES INC. 19 Vestry Street New York, NY 10013 NOTICE OF ANNUAL GENERAL MEETING OF TO BE HELD ON MARCH 24, 2023 INFORMATION CIRCULAR BRIGHT MINDS BIOSCIENCES INC. 19 Vestry Street New York, NY 10013 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MARCH 24, 2023 AND INFORMATION CIRCULAR This document requires immediate attention. If you are in doubt as to how to deal with the documents or matters referred to in this notice and information circular, you should immediately contact your advisor. BRIGHT MINDS BIOSCIEN
March 2, 2023	EX-99.1	January 20, 2023 January 20, 2023510 Burrard St, 3rd Floor Vancouver BC, V6C 3B9 www.computershare.com To: All Canadian Securities Regulatory Authorities NASDAQ Exchange Subject: BRIGHT MINDS BIOSCIENCES INC. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type :Annual General Meeting Record Date for Notice of Meeting :February 15,
March 2, 2023	EX-99.3	Proxy Card relating to Annual General Meeting of Shareholders to be held on
February 27, 2023	EX-99.1	Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023 -- First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT2C agonist, is underway in Australia -- -- Company has transitio Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023 - First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT2C agonist, is underway in Australia - - Company has transitioned from a discovery to a development organization – - Company to attend BIO-Europe Spring Conference in Basel, Switzerland, March 20-22, 2023 - Vancouver, British Columbia, February 27, 2023 – Bright Minds Biosciences Inc.
February 27, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File No. 001-40997 UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principa
February 17, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File No. 001-40997 UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principa
February 17, 2023	EX-99.1	NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES Bright Minds Biosciences Announces Non-Executive Director Appointment NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES Bright Minds Biosciences Announces Non-Executive Director Appointment - David Weiner, MD, brings extensive experience in the discovery and clinical development of novel therapeutics for neurological, psychiatric and rare
February 8, 2023	EX-99.1	BRIGHT MINDS BIOSCIENCES ANNOUNCES RECEIPT OF NASDAQ DEFICIENCY LETTER REGARDING INDEPENDENT DIRECTOR AND AUDIT COMMITTEE REQUIREMENTS EX-99.1 2 ex991-20230208drug.htm NEWS RELEASE BRIGHT MINDS BIOSCIENCES ANNOUNCES RECEIPT OF NASDAQ DEFICIENCY LETTER REGARDING INDEPENDENT DIRECTOR AND AUDIT COMMITTEE REQUIREMENTS Vancouver, British Columbia, February 8, 2023 – Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) announces that it has received a letter (the “Deficiency Letter”) from the Nasdaq
February 8, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File No. 001-40997 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive of
February 7, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File No. 001-40997 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive of
February 7, 2023	EX-99.1	Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three months ended December 31, 2022 and 2021 (Expressed in Canadian Dollars) EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three months ended December 31, 2022 and 2021 (Expressed in Canadian Dollars) 1 \| Page Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars) December 31, September 30, As at Notes 2022 (unaudited) 20
February 7, 2023	EX-99.3	Form 52-109F2 Certification of Interim Filings Full Certificate EX-99.3 4 exhibit99-3.htm EXHIBIT 99.3 Form 52-109F2 Certification of Interim Filings Full Certificate I, Ian McDonald, Chief Executive Officer of Bright Minds Biosciences Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of Bright Minds Biosciences Inc. (the "issuer") for the interim period ended December 31, 20
February 7, 2023	EX-99.4	Form 52-109F2 Certification of Interim Filings Full Certificate EX-99.4 5 exhibit99-4.htm EXHIBIT 99.4 Form 52-109F2 Certification of Interim Filings Full Certificate I, Ryan Cheung, Chief Financial Officer of Bright Minds Biosciences Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of Bright Minds Biosciences Inc. (the "issuer") for the interim period ended December 31, 202
February 7, 2023	EX-99.2	Studies Completed & Other Milestones Accomplished: EX-99.2 3 exhibit99-2.htm EXHIBIT 99.2 BRIGHT MINDS BIOSCIENCES INC. MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE FIRST QUARTER ENDED DECEMBER 31, 2022 (All amounts expressed in Canadian dollars, unless otherwise stated) This Management Discussion and Analysis ("MD&A") provides a detailed analysis of the business of Bright Minds Biosciences Inc. (the "Company") and describes the Company's financia
January 30, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File No. 001-40997 UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal
January 30, 2023	EX-99.1	Bright Minds Biosciences Announces Resignation of Board Member EX-99.1 2 ex991-20230109drug.htm NEWS RELEASE For Immediate Release Bright Minds Biosciences Announces Resignation of Board Member Vancouver, BC – January 9, 2023 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today
January 27, 2023	EX-99.1	BRIGHT MINDS BIOSCIENCES ANNOUNCES RECEIPT OF NASDAQ NOTIFICATION LETTER REGARDING MINIMUM BID PRICE DEFICIENCY BRIGHT MINDS BIOSCIENCES ANNOUNCES RECEIPT OF NASDAQ NOTIFICATION LETTER REGARDING MINIMUM BID PRICE DEFICIENCY Vancouver, British Columbia, January 27, 2023 – Bright Minds Biosciences Inc.
January 27, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File No. 001-40997 UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal
December 29, 2022	EX-13.1	Section 906 Certifications of CEO and CFO* EXHIBIT 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Bright Minds Biosciences Inc. on Form 20-F for the fiscal year ended September 30, 2021 filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certify that to the best of our
December 29, 2022	EX-12.1	Section 302(a) Certification of CEO* EXHIBIT 12.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ian McDonald, certify that: 1. I have reviewed this Annual Report on Form 20-F of Bright Minds Biosciences Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i
December 29, 2022	EX-4.26	Warrant Indenture dated August 30, 2022 between the Company and Computershare Trust Company of Canada*+ EX-4.26 5 exhibit4-26.htm EXHIBIT 4.26 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. BRIGHT MINDS BIOSCIENCES INC. as the Corporation and COMPUTERSHARE TRUST COMPANY OF CANADA as the Warrant Agent WARRANT INDENTURE Providing for the Issue of Warrants Dated as of August 30, 2022
December 29, 2022	EX-4.25	Agency Agreement between the Company and Eight Capital dated August 25, 2022*+ CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL.
December 29, 2022	EX-2.2	Description of Registrant's Securities* EXHIBIT 2.2 DESCRIPTION OF REGISTRANT'S SECURITIES The following securities of our Company are registered under section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"): our Company's common shares are listed on the Nasdaq Capital Market ("Nasdaq"), under the symbol "DRUG". Jurisdiction of Incorporation Our Company was incorporated under the Business Corporations Act (
December 29, 2022	20-F	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE AC
December 29, 2022	EX-4.24	Independent Contractor Agreement with Dr. Mark A. Smith dated December 1, 2022*+ EX-4.24 3 exhibit4-24.htm EXHIBIT 4.24 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. BRIGHT MINDS BIOSCIENCES INC. INDEPENDENT CONTRACTOR AGREEMENT THIS INDEPENDENT CONTRACTOR AGREEMENT (this "Agreement") is dated effective December 1, 2022 BETWEEN: BRIGHT MINDS BIOSCIENCES INC.
December 29, 2022	EX-12.2	Section 302(a) Certification of CFO* EXHIBIT 12.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ryan Cheung, certify that: 1. I have reviewed this Annual Report on Form 20-F of Bright Minds Biosciences Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
December 6, 2022	EX-99.1	BRIGHT MINDS BIOSCIENCES ANNOUNCES CLOSING OF NON-BROKERED PRIVATE PLACEMENT THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
December 6, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File No. 001-40997 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive of
November 29, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File No. 001-40997 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive of
November 29, 2022	EX-99.1	BRIGHT MINDS BIOSCIENCES ANNOUNCES NON-BROKERED PRIVATE PLACEMENT EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. BRIGHT MINDS BIOSCIENCES ANNOUNCES NON-BROKERED PRIVATE PLACEMENT Vancouver, British Columbia, November 28, 2022 - Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Min
November 23, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File No. 001-40997 6-K 1 f6k-20221123drug.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Addres
November 23, 2022	EX-99.1	Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer -- Dr. Smith is a 20-year pharmaceutical industry veteran with extensive central nervous system (“CNS”) clinical development expertise -- EX-99.1 2 ex991-20221123drug.htm NEWS RELEASE For Immediate Release Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer - Dr. Smith is a 20-year pharmaceutical industry veteran with extensive central nervous system (“CNS”) clinical development expertise - Vancouver, BC – November 23, 2022 – Bright Minds Biosciences (“Bright Minds,” “BMB”
September 8, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File No. 001-4099 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive o
September 8, 2022	EX-99.1	Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors NOT FOR DISTRIBUTION TO U.
September 8, 2022	EX-99.1	Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome -- In predictive animal models, BMB-101 demonstrated significant reduction in both the number and intensity of epileptic seizures -- For Immediate Release Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome - In predictive animal models, BMB-101 demonstrated significant reduction in both the number and intensity of epileptic seizures - Vancouver, BC ? August 31, 2022 ? Bright Minds Biosciences (?Bright Minds,? ?BMB? or the ?Company?) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that it has dosed the first patient in a Phase I trial (NCT 05397041) for its lead product, BMB-101, for the treatment of Dravet Syndrome and other medical indications.
September 8, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File No. 001-40997 B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offi
August 30, 2022	EX-99.1	PRESS RELEASE PRESS RELEASE August 30, 2022 THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
August 30, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File No. 001-40997 B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offi
August 29, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File No. 001-40997 B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offi
August 29, 2022	EX-99.3	AGENCY AGREEMENT AGENCY AGREEMENT August 25, 2022 Bright Minds Biosciences Inc.? 19 Vestry Street New York, NY 10013 Attention:Mr. Ian McDonald, President and Chief Executive Officer Dear Sir: The undersigned, Eight Capital, as the sole agent and bookrunner (the ?Agent?), understands that Bright Minds Biosciences Inc.? (the ?Corporation?) proposes to issue up to 2,858,000 units of the Corporation (?Units?) at a pr
August 29, 2022	EX-99.1	PROSPECTUS SUPPLEMENT To the Short Form Base Shelf Prospectus dated June 7, 2021 No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise.
August 29, 2022	EX-99.2	BRIGHT MINDS BIOSCIENCES INC. OVERNIGHT MARKETED PUBLIC OFFERING OF UNITS BRIGHT MINDS BIOSCIENCES INC. OVERNIGHT MARKETED PUBLIC OFFERING OF UNITS FINAL TERM SHEET AUG 23, 2022 A final short form base shelf prospectus containing important information relating to the securities described in this document has been filed with the securities regulatory authorities in each of the Provinces of Canada, other than Quebec. Copies of the final short form base shelf prospectus an
August 24, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File No. 001-40997 B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offi
August 24, 2022	EX-99.1	BRIGHT MINDS ANNOUNCES PRICING OF OVERNIGHT MARKETED OFFERING OF UNITS BRIGHT MINDS ANNOUNCES PRICING OF OVERNIGHT MARKETED OFFERING OF UNITS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
August 23, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File No. 001-40997 B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offi
August 23, 2022	EX-99.1	BRIGHT MINDS BRIGHT MINDS ANNOUNCES OVERNIGHT MARKETED OFFERING OF UNITS THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
August 18, 2022	EX-99.1	Bright Minds Biosciences Comments on Recent Trading Activity Bright Minds Biosciences Comments on Recent Trading Activity Vancouver, BC ? August 18, 2022 ? Bright Minds Biosciences (?Bright Minds,? ?BMB? or the ?Company?) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, is issuing this news release in response to a request by the Investment Industry Regulatory Organization of Canada (?IIROC?) to comment on recent trading activity of its stock.
August 18, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File No. 001-40997 B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offi
August 15, 2022	EX-99.1	Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three and nine months ended June 30, 2022 and 2021 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three and nine months ended June 30, 2022 and 2021 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars - Unaudited) June 30, September 30, As at Notes 2022 2021 $ $ ASSETS Current Assets Cash and cash equi
August 15, 2022	EX-99.3	Form 52-109F2R Certification of Refiled Interim Filings Form 52-109F2R Certification of Refiled Interim Filings This certificate is being filed on the same date that Bright Minds Biosciences Inc.
August 15, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File No. 001-40997 B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offi
August 15, 2022	EX-99.4	Form 52-109F2R Certification of Refiled Interim Filings Form 52-109F2R Certification of Refiled Interim Filings This certificate is being filed on the same date that Bright Minds Biosciences Inc.

DRUG / Bright Minds Biosciences Inc. - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

Grundläggande statistik

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?

Other Listings